Try our beta test site

12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: September 20, 2002
Last updated: June 18, 2008
Last verified: June 2008
The purpose of this study is to compare the safety of HMR 1964 and insulin aspart when used in external pumps with respect to catheter occlusions, GHb assessment, insulin doses, blood glucose parameters, hypoglycemic episodes, unexplained hyperglycemia, adverse events, laboratory data, and vital signs.

Condition Intervention Phase
Diabetes, Type I
Drug: Insulin glulisine (HMR1964)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: 12-Week, Multinational, Multicenter, Controlled, Open, 1:1 Randomized, Parallel Clinical Trial Comparing the Safety of HMR1964 and Insulin Aspart Used in Continuous Subcutaneous Insulin Infusion (CSII) in Subjects With Type 1 Diabetes Mellitus

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Frequency of catheter occlusions

Secondary Outcome Measures:
  • Unexplained hyperglycemia, parameters of glycemic control

Enrollment: 59
Study Start Date: May 2002
Study Completion Date: December 2002

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


Subjects meeting all of the following criteria will be considered for enrollment into the study:

  • Men and women above the age of 18.
  • Women are either not of childbearing potential (surgically sterile, or postmenopausal for more than 2 years) or are not pregnant and agree to use a reliable contraceptive measure for the duration of the study. Reliable contraceptive measures include the follows: systemic contraceptive (oral, implant, injections), diaphragm with intravaginal spermicide, cervical cap, intrauterine device, or condom with spermicide.
  • Type 1 diabetes mellitus as established in the medical history (for the purpose of this protocol: onset of diabetes under the age of 40 and has required continuous insulin therapy since diagnosis).
  • At least 1 year of continuous insulin treatment with at least 6 months of continuous subcutaneous insulin infusion treatment immediately prior to study entry.
  • Use of the same type of external insulin pump (MiniMed programmable pump, or Disetronic pump type H Tron Plus V 100 or D Tron) for at least 3 months prior to study entry.
  • HbA1c <8.5% measured at visit 1.
  • Ability and willingness to perform blood glucose monitoring using the sponsor-provided blood glucose meter and subject diary at home.

Informed consent must be obtained in writing for all subjects at enrollment into the study (see Section 12.3).


Subjects presenting with any of the following will not be included in the study:

  • Active proliferative diabetic retinopathy, as defined by the application of focal or panretinal photocoagulation or vitrectomy, in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require surgical treatment (including laser photocoagulation) during the study.
  • Diabetes other than type 1 diabetes mellitus.
  • History of serious ketosis episode requiring hospitalization in the 3 previous months.
  • History of abscess at the infusion site in the previous 3 months.
  • Pancreatectomised subjects.
  • Subjects who have undergone pancreas and or islet cell transplants.
  • Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol (see Section 6.2).
  • Treatment with any investigational drug in the last month before visit 1.
  • History of seizure disorders.
  • History of hypersensitivity to insulin or insulin analogues or any other excipients in the HMR1964 or insulin aspart formulation (see the Global Investigators Brochure [7] and the insulin aspart SPC [13] for a list of excipients).
  • Clinically relevant cardiovascular, hepatic, neurologic, endocrine, active cancer, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or would, in the opinion of the investigator, preclude the safe participation of the subject in this protocol.
  • History of drug or alcohol abuse.
  • Impaired hepatic function, as shown by but not limited to ALT or AST greater than twice the normal upper limit measured at visit 1.
  • Impaired renal function, as shown by but not limited to serum creatinine >177 micromol/L (>2.0 mg/dL) measured at visit 1.
  • Pregnancy (as determined by pregnancy blood test at visit 1) or breast-feeding.
  • Night shift workers.
  • Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
  • Subject unlikely to comply with protocol, e.g. an inability and unwillingness to participate in adequate training, an uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.
  • Employee of the sponsor or of sponsor representatives.
  • Subjects who have previously been treated with HMR1964.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00046150

Hospital de Rangueil
Toulouse, France, 31403
Sanofi-aventis Administrative Office
Berlin, Germany
Sanofi-aventis Administrative Office
Gouda, Netherlands
Sponsors and Collaborators
Study Director: ICD CSD Sanofi
  More Information

Additional Information:
Responsible Party: ICD Study Director, sanofi-aventis Identifier: NCT00046150     History of Changes
Other Study ID Numbers: HMR1964/3006
Study First Received: September 20, 2002
Last Updated: June 18, 2008

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin glulisine
Insulin Aspart
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on March 29, 2017